Skip to main content
. 2018 Sep 6;5:30. doi: 10.1186/s40779-018-0176-3

Table 2.

Improvements in AEOL-10150 in terms of use as an anti-chemical warfare agent released by Aeolus Pharmaceuticals

Time (M/D/Y) Contents
11/07/2007 AEOL-10150 protects SM-induced lung damage
04/23/2008 AEOL-10150 significantly protects against SM-exposure-induced lung and skin damage
02/09/2009 NIH Counter ACT program begins assessing treatment with Aeolus pharmaceuticals’ AEOL-10150 against SM gas damage
10/07/2009 AEOL-10150 protects lungs against SM damage in animal research
11/04/2009 AEOL-10150 protects lungs against Cl2 exposure in animal research
06/29/2010 AEOL-10150 significantly protects skin in preclinical SM damage studies
06/30/2010 AEOL-10150 protects lungs against SM exposure in animal research
10/10/2011 NIH grant of $12.7 million awarded to continue development of AEOL-10150 as a countermeasure to Cl2 and SM damage
10/24/2011 Aeolus pharmaceuticals announces NIH award to develop AEOL-10150 as a countermeasure to nerve agent exposure
07/30/2012 AEOL-10150 announced to eliminate oxidative stress and nerve damage following exposure to nerve agent
06/26/2013 AEOL-10150 significantly ameliorates survival in animals exposed to SM
07/02/2013 AEOL-10150 significantly ameliorates survival from nitrogen mustard exposure to skin in animals
09/11/2013 AEOL-10150 is the subject of a $4.3 million US government award defining countermeasures to nerve agents; data show that the drug significantly ameliorates survival in animals following exposure to pilocarpine, a nerve agent surrogate for soman and sarin gas
06/18/2014 Aeolus proclaims the publication of data demonstrating the efficacy of AEOL-10150 in an animal CEES model of SM skin damage
07/01/2014 Aeolus proclaims additional data demonstrating efficacy of AEOL-10150 as a medical treatment against exposure to nerve agents, SM and nitrogen mustard gas
03/31/2015 Aeolus receives a notice of allowance from the Israeli patent office for the use of AEOL-10150 and other Aeolus compounds to treat damage from exposure to SM
09/06/2016 Aeolus proclaims positive data demonstrating the efficacy of AEOL-10150 as a medical treatment against SM
09/19/2016 Aeolus proclaims publication of additional data showing the efficacy of AEOL-10150 in SM exposure in the journal Toxicological Sciences